[On Demand]
Eutilex is developing anti-tumor T cell therapy and immuno-oncology antibody therapeutics based on its own proprietary immuno-oncology technology.
An R&D oriented biotech in South Korea, Eutilex was publicly listed on the KOSDAQ in December 2018, with its current market cap of approximately $600M.

EU101: Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of cancer. EU101 is a superior 4-1BB mAb in side by side comparison demonstrated a higher anti-tumor efficacy than other 4-1BB antibodies, with a lower toxicity of 400mg/kg MTD as well as 200mg/kg NOAEL. P1/2 IND submission approved by US FDA on Jan. 14, 2021

GPC3 CAR-T: 4th generation autologous CAR-T equipped with IL-18 targeting HCC. Proven efficacy in vitro & in vivo. Toxicity study will be started in the 1st half of 2021. IND submission to Korea FDA (MFDS) and China FDA (NMPA) will be done in early 2022.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
anti-4-1BB mAb, autologous T cell therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided